Amnioinfusion Initiative

This study is currently recruiting participants.
Verified November 2008 by Università degli Studi di Brescia
Sponsor:
Collaborators:
Katholieke Universiteit Leuven
University of Milan
Catholic University, Italy
Brescia University
Information provided by:
Università degli Studi di Brescia
ClinicalTrials.gov Identifier:
NCT00787163
First received: November 6, 2008
Last updated: January 21, 2009
Last verified: November 2008

November 6, 2008
January 21, 2009
September 2008
September 2011   (final data collection date for primary outcome measure)
Survival of neonates/infants at discharge after serial amnioinfusions compared to survival after expectant management [ Time Frame: discharge of every neonate from NICU ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00787163 on ClinicalTrials.gov Archive Site
Gestational age of delivery (main secondary outcome) [ Time Frame: time of delivery for every case ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Amnioinfusion Initiative
Open Randomized Trial Comparing Perinatal Outcome Following Expectant Management Versus Amnioinfusion in PPROM <25 Wks With Persistent Oligohydramnios

The aim of this study is to compare perinatal survival in patients presenting with early spontaneous PPROM and persistent oligohydramnios, managed either conservatively or with serial amnioinfusions.

Early spontaneous Preterm Premature Rupture of Membranes (PPROM) is associated with high perinatal mortality. Due to pulmonary hypoplasia and preterm delivery, mortality exceeds 60% when PPROM occurs prior to 24 weeks. When oligohydramnios persists, it may raise to 90%. Morbidity in survivors is also significant. In uncontrolled series, serial amnioinfusions, which have acceptable invasiveness and are of limited complexity, mortality was reduced to 60%.

We propose an open, multicenter randomized trial comparing perinatal survival in patients presenting with early spontaneous PPROM and persistent oligohydramnios, managed either conservatively or with serial amnioinfusions. Inclusion criteria: Single pregnancy, early spontaneous PPROM < 24.3 weeks, oligohydramnios (deepest vertical pocket < 2 cm) for at least 4 days and no longer than 15 days at enrolment. The study is open and will be run through a dedicated password protected web site, and with a minimal number of outcome measures. Primary outcome: Survival till discharge from the NICU. Secondary outcomes: Latency time from PPROM to delivery, gestational age at birth, indication for delivery, number of days of ventilatory support, serious neurologic morbidity, neonatal sepsis prevalence, need for oxygen at 36 weeks post-conception.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Oligohydramnios
Procedure: amnioinfusion
serial amnioinfusions aimed at restoring amniotic fluid volume
  • Experimental: 1
    amnioinfusion
    Intervention: Procedure: amnioinfusion
  • No Intervention: 2
    expectant management
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
82
December 2013
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients above 18 years, who are able to consent, with
  2. Singleton pregnancy
  3. with a normal structural examination as much as possible;
  4. At least 2 US examination after pPROM for gestational age confirmation and diagnosis of persistent oligohydramnios
  5. Follow up ultrasound examinations weekly in the treatment group
  6. Acceptance of randomisation and to comply with the protocol

Exclusion Criteria:

  1. Maternal contra-indications to intervention or prolongation of pregnancy, including severe medical conditions in pregnancy that make fetal intervention riskful;
  2. Preterm labour defined as contractions >6/hour associated with cervical changes, cervix shortened (<15 mm at randomization),
  3. Cervical cerclage in place
  4. Chorioamnionitis, defined as 2 or more of the following: maternal temperature>38 degrees, foul-smelling vaginal discharge, uterine tenderness, fetal tachycardia>170 bpm, white blood cell count >18,000
  5. Fetal structural anomaly detected at prenatal ultrasonography, or fetal chromosomal abnormalities involving autosomes
  6. Previous invasive procedure in this index pregnancy
  7. Fetal condition mandating immediate delivery
  8. Severe bleeding
  9. Maternal HIV and HCV infection
  10. Multiple gestation
Female
18 Years to 45 Years
No
Contact: Anna Locatelli, MD +39 039 233 4720 anna.locatelli@unimib.it
Italy
 
NCT00787163
Amnioinfusion-001
Yes
Anna Locatelli, University of Milano Bicocca
Università degli Studi di Brescia
  • Katholieke Universiteit Leuven
  • University of Milan
  • Catholic University, Italy
  • Brescia University
Principal Investigator: Anna Locatelli, MD University of Milano Bicocca
Study Chair: Patrizia Vergani, MD University of Milano Bicocca
Università degli Studi di Brescia
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP